News | November 18, 2008

Dilon Technologies, Terason Partner to Offer Expanded Breast Imaging Options

November 18, 2008 - Dilon Technologies Inc. said today that they have formed an alliance with Terason Ultrasound to offer an expanded imaging capability when molecular breast imaging and ultrasound may be required.

BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers, particularly for women with high risk factors or that present with questionable mammograms. With BSGI, metabolic activity is assessed and cancerous cells generally display as "hot spots."

Terason is a leader in integrating patented microsystem technology with an Apple MacBook Pro PC. The Terason t3000 Ultrasound System reportedly offers quality imaging performance with the portability and functionality of a laptop.

When used as a complement to the Dilon 6800 Gamma Camera, physicians are able to move from BSGI to ultrasound without leaving the exam room.

The Terason t3000 reportedly offers best-in-class image quality; ease of use with a dual user interface; and an integrated information management and communications protocol in one system. For quick on-the-spot, accurate scanning in a wide array of clinical applications, transducers quickly connect to the system allowing technicians to perform an ultrasound exam at the point of patient care. Terason's patented high-density, beam-forming architecture provides a superior performance cost-effective ultrasound solution.

The ultrasound system is built upon an industry respected combination of the Apple PC coupled with Windows Operating System to provide seamless networking capabilities, compatibility with various applications, standard connections, and software updates. The system includes DICOM, wireless, integrated CD/DVD and USB capability.

For more information: www.terason.com, www.dilon.com

Related Content

Breast Density Advocate Nancy M. Cappello Passes Away

Nancy Cappello. Image courtesy of AreYouDense.org.

News | Breast Density | November 15, 2018 | Jeff Zagoudis, Associate Editor
Imaging Technology News extends its condolences to the family, friends and colleagues of Nancy M. Cappello, Ph.D., who...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
SuperSonic Imagine Introduces Aixplorer Mach 30 Ultrasound at The Liver Meeting
Technology | Ultrasound Imaging | November 14, 2018
SuperSonic Imagine recently exhibited at The Liver Meeting, held Nov. 9-13 in San Francisco, where the company...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
New Robotic Arm System Optimizes Testing of Ultrasound Probes

Image courtesy of Esaote

News | Ultrasound Imaging | November 09, 2018
Medical imaging company Esaote and The BioRobotics Institute of Scuola Superiore Sant’Anna in Pisa, Italy, have...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | Breast Imaging | November 07, 2018 | By Jeff Zagoudis
Breast imaging technology has experienced major growth over the last decade or so, and a new report suggests the mark
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages